Invest in Paxman Scalp Cooling

In 2017 we took some of the most important steps in Paxman’s history. We launched operations in the US following the FDA clearance in April 2017, and we listed our parent company on Nasdaq First North Growth Market in Sweden in June 2017.

We ask you to join us in this mission.

In preparation for the listing, an oversubscribed share issue of approximately SEK 30,4 million was conducted. The share price has reflected the company’s strong progression and has continued to strengthen highlighting the exciting potential of Paxman.

At Paxman, we are not only building a strong and financially viable business but improving the lives of cancer patients around the world. This is both a financial and social investment.